Experimental HIV vaccine shows promise in early trial
NCT ID NCT04985760
First seen Nov 06, 2025 · Last updated May 12, 2026 · Updated 35 times
Summary
This early-stage study tested an experimental HIV vaccine called Trimer 4571 in 32 adults with HIV who were already on effective antiretroviral therapy (ART). The main goals were to see if the vaccine is safe and well-tolerated, and whether it can help the immune system produce broadly neutralizing antibodies (bnAbs) against HIV. Participants received either a low dose, a high dose, or a placebo shot. The results will help determine if this vaccine approach is worth studying further.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AIDS Clinical Trials Unit/The Ohio State University
Columbus, Ohio, 43210, United States
-
University of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States
Conditions
Explore the condition pages connected to this study.